Currently, Iovance Biotherapeutics Inc [IOVA] is trading at $3.63, up 5.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IOVA shares have gain 2.54% over the last week, with a monthly amount drifted -32.15%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $17. Previously, Piper Sandler downgraded its rating to Neutral on July 29, 2024, and dropped its price target to $10. On November 20, 2023, Goldman initiated with a Buy rating and assigned a price target of $12 on the stock. Barclays reiterated its Overweight rating and decreased its price target to $18 on September 18, 2023. Wells Fargo upgraded its rating to a Overweight and raised its price target to $17 on May 30, 2023. In a note dated January 27, 2023, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $11 to $14.
This stock has fluctuated between a low of $3.33 and a high of $15.18 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $11.5 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $3.63 at the most recent close of the market. An investor can expect a potential return of 216.8% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Trailing Twelve Months sales for Iovance Biotherapeutics Inc [NASDAQ:IOVA] were 164.07M which represents 15189.21% growth. Gross Profit Margin for this corporation currently stands at 0.18% with Operating Profit Margin at -2.41%, Pretax Profit Margin comes in at -2.29%, and Net Profit Margin reading is -2.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.51 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.48 points at the first support level, and at 3.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.72, and for the 2nd resistance point, it is at 3.81.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Iovance Biotherapeutics Inc [NASDAQ:IOVA] is 3.74. As well, the Quick Ratio is 3.31, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 7.25, the price to book ratio is 1.56.
Transactions by insiders
Recent insider trading involved Maynard Ryan D, Director, that happened on Nov 12 ’24 when 50000.0 shares were sold. Director, Maynard Ryan D completed a deal on Nov 12 ’24 to buy 50000.0 shares.
